IP Library › Granted Patent US 9,346,871
Granted Patent B2
US 9,346,871 · App. 13/936,650 · Granted May 24, 2016

Engineered CXCL12 alpha locked dimer polypeptide

Inventors: Brian F. Volkman (Muskego, WI); Christopher T. Veldkamp (Milwaukee, WI); Francis C. Peterson (Racine, WI); Thomas Sakmar (New York, NY); Christoph H. Seibert (Frankfurt am Main, DE)
Assignees: The Medical College of Wisconsin; The Rockefeller University
C07K14/521C07K14/522A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,346,871
App. No.
13/936,650
Granted
May 24, 2016
Kind
B2
Abstract

The present invention provides a novel CXCL12-α 2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Claims (1)

1. A method of inhibiting HIV entry into CXCR4 + T cells in a subject comprising administering to the subject a composition comprising a CXCL12α 2 locked dimer polypeptide in an amount effective to inhibit HIV entry into the CXCR4 + T cells, wherein the CXCL12α 2 locked dimer polypeptide comprises two covalently linked CXCL12 monomers, each of which comprises the amino acid sequence of SEQ ID NO:1.

Continuity (4)
Division 12956514 · Nov 30, 2010
Continuation 12380308 · Sep 26, 2009
Provisional Application 61067273 · Feb 27, 2008
Related Publication 20130316944A1 · Nov 28, 2013